跳至主要内容
临床试验/NCT05850468
NCT05850468尚未招募不适用

Assistant Professor of Anesthesia, Intensive Care and Pain Management

Ain Shams University1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2023年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
入组人数
140
试验地点
1
主要终点
number of patients (percentage) having intraoperative systolic hypertension

研究概览

简要总结

opioid free anesthesia consists of combination of pharmacological and non pharmacological modalities that target different pathways of pain mechanism. combining myofascial plane blocks with infusion of adjuvants such as lidocaine or dexmedetomidine can offer equivalent intraoperative hemodynamic stability compared to that of opioid with better pain control postoperatively. this study will investigate the efficacy of combined erector spina block with lidocaine and dexmedetomidine infusion as opioid sparing anesthesia in spine surgeries

详细描述

patients who will undergo spine surgery will be allocated into two groups. after general anesthesia, bilateral erector spine block will be applied in both groups. group A will have intraoperative fentanyl infusion and group B will have lidocaine and dexmedetomidine infusion in 50 ml syringe till end of surgery

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • spine surgery ASAI,II

排除标准

  • revision surgery hypotension bradycardia

研究组 & 干预措施

traditinal balanced anesthesia

Active Comparator

fentanyl infusion after general anesthesia and erector spinea block

干预措施: fentanyl infusion after general anesthesia and erector spinea block (Drug)

opioid free anesthesia

Experimental

lidocaine and dextometidine infusion after general anesthesia and erector spinea block

干预措施: lidocaine 2% and dextometometidine infusion after general anesthesia and erector spinea block (Drug)

结局指标

主要结局

number of patients (percentage) having intraoperative systolic hypertension

时间窗: during operation(intraoperatively)

blood pressure more than 160 mmhg

number of patients(percentage) having tachycardia

时间窗: during operation(intraoperatively)

heart rate more than 100 beat /minute

次要结局

  • VAS score(every 30 minutes for 2 hours postoperatively)
  • incidence of bradycardia(intraoperatively)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.Serious epithelial ovarian cancer including primary peritoneal and fallopian tube malignanciesMedDRA version: 17.1Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-003812-36-ESMorphotek Inc214
进行中(未招募)
1 期
An experimental study in men and women with head and neck cancer to test the safety, tolerability and the effects of addition of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activate part of the immune systemHPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)MedDRA version: 20.0 Level: PT Classification code 10031098 Term: Oropharyngeal cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-000789-13-FRISA Therapeutics B.V.164
进行中(未招募)
不适用
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First RelapseFirst relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignanciesMedDRA version: 14.0Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2008-005872-29-ATEisai Limited1,080
进行中(未招募)
1 期
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.Serious epithelial ovarian cancer including primary peritoneal and fallopian tube malignanciesMedDRA version: 20.0Level: PTClassification code 10033160Term: Ovarian epithelial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-003812-36-BEMorphotek Inc210
进行中(未招募)
1 期
An experimental study in men and women with head and neck cancer to test the safety, tolerability and the effects of addition of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activate part of the immune systemHPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)MedDRA version: 20.0Level: PTClassification code 10031098Term: Oropharyngeal cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-000789-13-HUISA Therapeutics B.V.164